Home › Trials › NCT06941844

Evaluating MM120 for Major Depressive Disorder

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Emerge

Phase 3 Interventional Mind Medicine, Inc. · NCT06941844

This study is testing a new treatment called MM120 to see if it can help adults with Major Depressive Disorder feel better compared to a placebo.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment140 (estimated)
Ages18 Years to 74 Years
SexAll
SponsorMind Medicine, Inc. Industry-sponsored
Locations26 sites (Fayetteville, Arkansas and 25 other locations)
Trial IDNCT06941844 on ClinicalTrials.gov

What this trial studies

This Phase 3 trial aims to assess the efficacy of MM120, a compound derived from LSD, in treating Major Depressive Disorder (MDD) compared to a placebo. The study will enroll around 140 adults aged 18 to 74 who meet specific diagnostic criteria for MDD. Participants will undergo a 12-week double-blind period followed by a 40-week open-label extension, where they will be monitored for safety and symptom improvement. The trial seeks to provide insights into the potential benefits of MM120 in managing depressive symptoms.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 74 with a confirmed diagnosis of Major Depressive Disorder experiencing a major depressive episode.

Not a fit: Patients with other significant psychiatric disorders or unstable medical conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could offer a novel therapeutic option for patients suffering from Major Depressive Disorder.

How similar studies have performed: Previous studies exploring psychedelic compounds for depression have shown promising results, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Diagnosis of MDD per DSM-5
2. Male or female aged 18 to 74
3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration
4. MADRS Total Score ≥26
5. CGI-S Score ≥4

Exclusion Criteria:

1. Certain psychiatric disorders (other than major depressive disorder)
2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine
4. Any clinically significant unstable illness

Where this trial is running

Fayetteville, Arkansas and 25 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Major Depressive Disorder
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.